Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €53.82 EUR
Change Today +1.03 / 1.95%
Volume 1.2K
As of 3:38 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

bristol-myers squibb co (BRM) Snapshot

Open
€53.73
Previous Close
€52.79
Day High
€54.30
Day Low
€53.55
52 Week High
07/21/15 - €65.30
52 Week Low
10/15/14 - €37.76
Market Cap
89.8B
Average Volume 10 Days
2.6K
EPS TTM
--
Shares Outstanding
1.7B
EX-Date
07/1/15
P/E TM
--
Dividend
€1.49
Dividend Yield
2.34%
Current Stock Chart for BRISTOL-MYERS SQUIBB CO (BRM)

bristol-myers squibb co (BRM) Details

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular. The company’s products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Erbitux, an IgG1 monoclonal antibody that targets and blocks the epidermal growth factor receptor; and Sprycel, a multi-targeted tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia. Its products also comprise Yervoy, a monoclonal antibody for the treatment of patients with metastatic melanoma; Abilify, an antipsychotic agent for adult patients with schizophrenia, bipolar mania disorder, and major depressive disorder; Orencia for use in treating patients with moderately to severely active rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders. In addition, it is developing Opdivo, a human monoclonal antibody, which is in Phase III trials for non-small cell lung cancer, renal cell cancer, and melanoma; Beclabuvir, a non-nucleoside NS5B inhibitor that is in Phase III development for the treatment of HCV; Elotuzumab, a humanized monoclonal antibody, which is in Phase III trials for the treatment of multiple myeloma; and BMS-663068, an investigational compound that is being studied in HIV-1. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

25,000 Employees
Last Reported Date: 02/13/15
Founded in 1887

bristol-myers squibb co (BRM) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $916.0K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $910.5K
Chief Scientific Officer, Executive Vice Pres...
Total Annual Compensation: $875.0K
Executive Vice President, General Counsel and...
Total Annual Compensation: $849.8K
Compensation as of Fiscal Year 2014.

bristol-myers squibb co (BRM) Key Developments

FDA Approves U.S. Product Labeling Update for Sprycel® (dasatinib)

Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved an update to the Sprycel® (dasatinib) product labeling. The labeling now includes five-year efficacy and safety data in adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP) and seven-year data in CP Ph+ CML patients who are resistant1 or intolerant2 to prior therapy, including Gleevec®3 (imatinib mesylate). Sprycel is associated with the following warnings and precautions: myelosuppression, bleeding-related events, fluid retention, cardiovascular events, pulmonary arterial hypertension, QT prolongation, severe dermatologic reactions, tumor lysis syndrome, and embryo-fetal toxicity.

Bristol-Myers Squibb Introduces I-O RPM Program in US

Bristol-Myers Squibb Company has introduced the Immuno-Oncology Rare Population Malignancy, or I-O RPM, program in the US. The I-O RPM program is a multi-institutional initiative with academic-based cancer centers focused on the clinical investigation of Immuno-Oncology therapeutics as potential treatment options for patients with high risk, poor prognostic cancers, defined as a rare population malignancy. As part of the I-O RPM program, Bristol-Myers Squibb, the Robert H. Lurie Comprehensive Cancer Center of Northwestern University (Lurie Cancer Center) and the Northwestern Medicine Developmental Therapeutics Institute (NMDTI) are pleased to announce that they have entered into a collaboration agreement. The Lurie Cancer Center and NMDTI will conduct a range of early phase clinical studies and Bristol-Myers Squibb will fund positions within the NMDTI Developmental Therapeutics Fellowship program.

Bristol-Myers Squibb Launches Nivolumab in UK

Bristol-Myers Squibb has introduced its nivolumab in the United Kingdom. The product is intended to treat locally advanced or metastatic squamous non-small cell lung cancer after chemotherapy in adult patients. It is the first in a new class of medicines to be approved for lung cancer and it works by harnessing the immune system's ability to find and fight cancer. The approval was based on results from the pivotal Phase III, CheckMate -017 study that assessed the efficacy and safety of nivolumab in adult patients with advanced squamous-cell NSCLC, whose disease had progressed during or after one prior platinum containing chemotherapy regimen.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BRM:GR €53.82 EUR +1.03

BRM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $63.98 USD -0.53
Allergan plc $308.01 USD -3.99
Eli Lilly & Co $83.19 USD -0.55
Medtronic PLC $73.56 USD +0.04
Novo Nordisk A/S kr369.50 DKK -0.60
View Industry Companies
 

Industry Analysis

BRM

Industry Average

Valuation BRM Industry Range
Price/Earnings 56.9x
Price/Sales 6.2x
Price/Book 6.7x
Price/Cash Flow 56.7x
TEV/Sales 5.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BRISTOL-MYERS SQUIBB CO, please visit www.bms.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.